Quality standard
Update information
Update information
December 2021: Changes have been made to align this quality standard with the updated NICE guideline on prostate cancer. Statement 2 has been amended so that 'Cambridge Prognostic Group (CPG) 1' replaces 'low-risk' localised prostate cancer and people in the population specified are now offered active surveillance. Statement 3 has been changed with 'CPG 2, 3, 4 and 5' replacing 'intermediate or high-risk' localised prostate cancer and to include people with locally advanced prostate cancer. Links, definitions and source guidance references have been updated throughout.
May 2019: Changes have been made to align this quality standard with the updated NICE guideline on prostate cancer. Statement 2 has been amended so that active surveillance is now an equal choice alongside prostatectomy and radiotherapy for people with low-risk localised prostate cancer, in line with the updated guideline. Terminology has been changed from 'men' to 'people' throughout to ensure that people who do not identify as men but who have a prostate are included in the guideline. References and links to source guidance have also been updated.